We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


EpiStem Awarded Further Long Term Funding for NIH Biodefence Programme

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
EpiStem plc has announced that it has been reappointed for up to five years to provide preclinical testing services as a subcontractor to the U.S. National Institutes of Health's (NIH) Radiation/Nuclear Medical Countermeasure Product Development Support Services Contract, which has been awarded to the University of Maryland School of Medicine (UMSOM) in Baltimore.

In the first subcontract commencing in 2006, EpiStem received approximately 3.5 million USD to develop models and evaluate novel drugs that can treat the effects of radiation damage to the gastrointestinal tract. The new five year subcontract is expected to extend and grow the scope of the collaborative relationship.

This UMSOM programme, referred to as the Medical Countermeasures against Radiological Threats (MCART) programme, is funded by the NIH's National Institute of Allergy and Infectious Diseases (NIAID), and aims to identify and develop new treatments for use in the event of a radiological or nuclear incident.

As a subcontractor, EpiStem is a member of the research consortium which has been awarded the contract and comprises radiobiology experts, each with specialist knowledge of the effects of radiation in different tissues of the body. EpiStem's role is to provide specialized gastrointestinal models to assess the efficacy and mode of action of new drugs entering the programme.

In the previous subcontract, the Company refined drug screening methods, further characterized the biology of radiation damage in the gastrointestinal tract and assessed several new drug candidates. Other members of the consortium, which is led by the UMSOM, include Indiana University School of Medicine and Duke University in the USA. EpiStem is the only research facility outside of North America within the consortium.